XPD751和XRCC1399联合基因型与非小细胞肺癌化疗毒性的关系

Relationship between chemotherapy toxicity reaction of non-small cell lung cancer and combined genotypes of XPD751 and XRCC1399

目的探讨DNA损伤修复基因XPD751和XRCC1399的联合基因型与晚期非小细胞肺癌(NSCLC)以铂类为基础的化疗毒副反应的关系。方法以聚合酶链反应(PCR)结合限制性片段长度多态性(RFLP)检测108例NSCLC患者的XPD751和XRCC1399多态基因型,并比较不同联合基因型与化疗毒副反应的关系。使用STATA 8.0软件非条件Logistic回归计算比值比(OR)及其95%可信区间(95%CI)。结果 44例同时携带XPD751Lys/Lys和XRCC1399Gln/Gln基因,38例同时携带XPD751Lys/Lys和XRCC1399Arg/Gln基因,6例同时携带XPD751Lys/Lys和XRCC1399Arg/Arg基因,14例同时携带XPD751Lys/Gln和XRCC1399Gln/Gln基因,6例同时携带XPD751Lys/Gln和XRCC1399Arg/Gln基因,未发现同时携带XPD751Lys/Gln和XRCC1399Arg/Arg基因者。40例未出现化疗毒副反应,68例至少发生1种毒副反应,共有59例发生骨髓毒性,16例发生消化道毒性,9例发生肝功能损害。携带XPD751Lys/Lys-XRCC1399Gln/Gln基因型的患者与其他联合基因型患者的总体毒性发生率、肝脏毒性发生率和消化道毒性发生率的差别均无统计学意义(P>0.05);携带XPD751Lys/Lys-XRCC1399Arg/Gln基因型的患者与其他联合基因型患者的骨髓毒性发生率的差别无统计学意义(P>0.05)。结论未发现XPD751和XRCC1399联合基因型与NSCLC患者接受以铂类为基础的化疗毒副反应有明显相关。

Objective To study the relationship between chemotherapy toxicity reaction of non-small cell lung cancer （NSCLC） based on platinum and the combined genotypes of the DNA damage repair genes XPD751 and XRCC1399. Methods The polymorphism gcnntypes of XPD751 and XRCC1399 of 108 NSCLC patients were detected by polymerase chain reaction （PCR） based restriction fragment length polymorphism （RFLP） methods. The relationship between different combined genotypes and chemotherapy toxicitics reaction were compared. Odds ratios （ORs） and it＇s 95% confidence intervals were calculated by unconditional Logistic regression of STATA 8.0 statistical software. Results Forty-four patients carried XPD751Lys/Lys and XRCC1399C, ln/C, ln genes,38 patients carried XPD751Lys/Lys and XRCC1399Arg/Gln genes,6 patients carried XPD751Lys/Lys and XRCC1399Arg/Arg genes, 14 patients carried XPD751Lys/Gln and XRCC1399Gtn/GIn genes ,6 patients carried XPD751Lys/ Gln and XRCC1399Arg/GIn genes, while no patient carried XPD751Lys/Gln and XRCC1399Arg/Arg genes at the same time. Forty patients did not appear reaction of chemotherapy toxicity, one kind of toxicity reaction at least was observed in 68 patients, marrow toxicity reaction was observed in 59 patients and gastrointestinal toxicity reaction was observed in 16 patients, hepatic damage was observed in 9 patients. There was no statistical significance in the incidence rate of overall toxicity reaction, liver toxicity reaction and gastrointestinal toxicity reaction among the patients carried XPD751Lys/Lys-XRCC1399Gln/Gln gene and carried the others combined genotypes （ P 〉 0.05 ）. There was no statistical significance in the incidence rate of marrow toxicity reaction among the patients carried XPD751Lys/Lys-XRCC1399Arg/Gln gene and carried the others combined genotypes（ P 〉 0. 05 ）. Conclusion There was no remarkable relationship between chemotherapy toxicity reaction of NSCLC patients based on platinum and combined genotypes of XPD751 and XRCC1399.